.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers recently conducted a significant trial comparing different targets for Meige syndrome DBS. This randomized, controlled, double-blind multicenter study evaluated the safety and efficacy of the globus pallidus internus (GPi) and the subthalamic nucleus (STN). Consequently, clinicians now have high-quality evidence to guide surgical decisions for this challenging movement disorder. Both targets demonstrated comparable improvements in motor symptoms and patient quality of life.
The 62 participants received either GPi or STN stimulation. After a 12-month follow-up, both groups achieved nearly 60% improvement in motor function scores. Furthermore, mood and cognitive stability remained consistent across both cohorts. However, the STN-DBS group required significantly less total electrical energy than the GPi group. Notably, researchers used lead-mapping technology to identify precise stimulation "sweet spots." For GPi-DBS, the posterolateral dorsal pallidum offered the best outcomes. In contrast, the dorsal STN proved to be the ideal site for the subthalamic target.
Identifying which patients respond best to therapy is vital for clinical success. The study found that preoperative impairment in speech and swallowing negatively impacts efficacy. Specifically, patients with higher disability scores in these areas experienced less overall benefit from surgery. Therefore, clinicians should carefully screen these subscores during preoperative assessments. This trial provides a refined roadmap for functional neurosurgeons treating refractory cases of Meige syndrome.
Both the GPi and STN targets provide similar motor improvements and safety profiles. However, STN-DBS typically requires lower electrical energy settings to achieve these results.
The trial showed that Meige syndrome DBS significantly enhances quality of life, mood, and motor control, with results remaining stable for at least one year post-surgery.
Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Wu Y et al. Pallidus internus versus subthalamic nucleus deep brain stimulation for Meige syndrome: a randomized, controlled, double-blind multicenter trial. J Neurosurg. 2026 Feb 20. doi: 10.3171/2025.9.JNS251188. PMID: 41719550.
Guizhi Wu et al. Globus pallidus internus versus subthalamic nucleus deep brain stimulation for Meige syndrome: a retrospective study on short- and long-term efficacy. J Neurosurg. 2026 Feb 6. doi: 10.3171/2025.9.JNS251420. PMID: 41650451.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Randomized multicenter trial finds GPi and STN DBS equally effective for Meige syndrome, with specific stimulation sweet spots identified for each target....
6 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
